Delbios Pharmaceuticals SL, new ICMAB-CSIC spin-off, secures Neotec 2025 funding
- Press Links:
Delbios Pharmaceuticals SL, a new spin-off from the Institute of Materials Science of Barcelona (ICMAB-CSIC), has been awarded funding from the prestigious Neotec 2025 Programme (CDTI). The company, created by researchers from the Nanomol-Bio group, aims to bring innovative nanomedicines from advanced preclinical stages to early clinical development, translating cutting-edge research into real therapeutic solutions.
Newspapers, Press Release, TT News, Breaking News, timeline, ICMAB in the media
- Hits: 1654










